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Abstract
Background: The incidence of multiple primary malignancies (MPM) has increased sharply in recent decades.
However, the clinical characteristics and prognosis of MPM patients involving lung cancer were not fully elucidated.
This retrospective study was designed to explore the clinical characteristics and prognosis of MPM patients
involving lung cancer in the People’s Republic of China.
Methods: Of 5405 lung cancer cases diagnosed at the Guangdong Lung Cancer Institute between 2005 and 2013,
we analyzed 185 patients (3.4 %) with MPM involving lung cancer.
Results: Among 185 patients with MPM involving lung cancer, 10 (5.4 %)had three malignancies and 175
(94.6 %) had two malignancies. 10 patients with three malignancies were excluded from the analysis to avoid
misunderstanding. Of 175 accompanying malignancies, 64 (36.6 %) were synchronous MPM patients and 111
(63.4 %) were metachronous MPM patients; 49 (28.0 %) were lung cancer first MPM patients and 126 (72.0 %) were
other cancer first MPM patients. The most frequent accompanying malignancy was colon cancer (25/175), followed by
rectal cancer (18/175), esophageal cancer (17/175), and thyroid cancer (13/175). Metachronous MPM patients showed
significantly better overall survival (OS) than synchronous MPM, with a median OS of 72.8 (range 12.2–391.0) and 12.9
(range 0.8–86.3)months, respectively (P < 0.001). Cox regression analysis revealed that time of occurrence and stage
were independent factors for OS.
Conclusions: Colorectal cancer, esophageal cancer, and thyroid cancer were the tumors that most frequently
accompanying lung cancer. Metachronous MPM patients showed significantly better OS compared with synchronous
MPM patients.
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Background
Multiple primary malignancies (MPM) are defined by
the presence of two or more independent primary malig-
nancies in the same or different organs in an individual
patient [1]. One of the earliest systematic studies of
MPM was performed by Warren and Gates in 1932 [2].
The development of MPM is not a rare phenomenon.
Based on an analysis of several studies, the incidence of
MPM was estimated at 0.73–5.2 % in all tumor patients.
This wide variation is related to the diverse experiences
of doctors and different diagnostic tools used at different
hospitals [3–5]. The incidence of MPM has increased
dramatically in recent decades [6]. Lung cancer is one of
the most commonly diagnosed cancers and causes the
highest number of cancer-related deaths [7]. Improve-
ments in diagnostic tools and treatment modalities,
including molecularly targeted therapy, have resulted in
great advances in lung cancer prognosis. Consequently,
patients are surviving long enough to develop subse-
quent primary malignancies. Although the incidence of
MPM has risen in recent decades, research on MPM
involving lung cancer remains limited, especially in
Chinese patients. This study retrospectively focused on
the incidence, clinical features, and prognosis of MPM
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Methods
Definition of second primary malignancy
MPM were defined according to Warren and Gate’s cri-
teria [2]: (1) each tumor had to show definite features of
malignancy; (2) each cancer had to be anatomically sep-
arate and distinct; (3) the possibility that one cancer was
a recurrence or metastatic lesion of the first cancer had
to be ruled out; and (4) the subsequent primary malig-
nancies had to be present in either the same or different
organs. We selected MPM patients based on the above
criteria, except for cancers occurring in the same organ.
MPM patients can be divided into two categories depend-
ing on the interval between tumor diagnoses. Synchronous
MPM patients were defined as those occurring simultan-
eously or within 6 months of each other, whereas meta-
chronous MPM patients were defined as those occurring
more than 6 months apart [8]. In lung cancer first (LCF)
MPM, lung cancer occurred before the secondary primary
malignancy, while in other cancer first (OCF) MPM, the
other primary malignancy occurred before lung cancer.
Patients
Between January 2005 and July 2013, 185 patients at the
GLCI experienced MPM involving lung cancer out of a
total of 5,405 lung cancer patients. The 185 MPM pa-
tients were diagnosed comprehensively based on detailed
medical history, a complete physical examination, appro-
priate radiographic and/or endoscopic examinations,
and pathological results, which were reviewed separately
by two pathologists. We arbitrarily chose 70 years as the
cut-off to divide into young and old patients. Overall
survival (OS) was calculated from the date of the first
primary cancer diagnosis to the date of death or last
follow-up of either the first or subsequent malignancy.
Curative therapy was defined as treatment according to
tumor classification; e.g., surgery for colorectal, gastric,
lung, esophageal, cervical, breast, thyroid, and renal can-
cers, and radio-chemotherapy for nasopharyngeal cancer
and non-Hodgkin lymphoma. Palliative treatment was
defined as treatment that is non-curative but to relieve
suffering, which included best supportive treatment. The
patients were followed up through out-patient depart-
ment visits or telephone calls. During the follow-up
(median follow-up time, 41.2 months), 10 patients
(5.4 %) were lost to follow-up, 76 (41.1 %) were still
alive, and 99 (53.5 %) died.
Detection of EGFR mutation status
Of 175 MPM patients with two malignancies, the EGFR
mutation status of only 84 patients were reviewed. The
EGFR mutation status were detected by amplification
refractory mutation system (ARMS) -polymerase chain
reaction or direct sequencing.
Ethics statement
The study protocol was approved by the Institutional
Review Board of Guangdong General Hospital and con-
formed to the ethical guidelines of the Declaration of
Helsinki.
Statistical analysis
Chi-square test, Fisher’s exact test, or a nonparametric
test, where appropriate, was used for statistical compari-
sons. The Kaplan–Meier method was applied to univariate
survival analysis. A multivariate model was built to evalu-
ate the risk associated with prognostic factors. P-values
less than 0.05 were considered statistically significant. All
statistical analyses were performed using SPSS version
13.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Of the lung cancer cases diagnosed at GLCI between
January 2005 and July 2013, the incidence of MPM
involving lung cancer was 3.4 % (185/5405). Of the 185
patients with MPM involving lung cancer, 175 (94.6 %)
had two malignancies and 10 (5.4 %) had three malig-
nancies. 10 patients with three malignancies were ex-
cluded from the analysis to avoid misunderstanding.
There were 175 accompanying malignancies among the
175 MPM patients with lung cancer. Of the 175 accom-
panying malignancies, 64 (36.6 %) were synchronous
MPM patients and 111 (63.4 %) were metachronous
MPM patients, 49 (28.0 %) were LCF MPM patients,
and 126 (72.0 %) were OCF MPM patients. Compared
with metachronous MPM and OCF MPM, synchronous
MPM and LCF MPM were less common. The median
age at lung cancer diagnosis was 64 (range 33–88) years,
and the median age at diagnosis of other cancers was 62
(range 23–89) years. In subgroup analyses, there were
more young patients than old patients either in the
metachronous MPM group(57.7 % vs 42.3 %, P = 0.05)
or in the synchronous MPM group(73.4 % vs 26.6 %, P =
0.05). In addition, there are more cases of never smoker
patients both in the metachronous MPM group(73.9 % vs
26.1 %, P = 0.043) and the synchronous MPM group(57.8 %
vs 42.2 %, P = 0.043). The difference of clinical features
between LCF MPM patients and OCF MPM patients did
not reach significance (Table 1).
Malignancies accompanying lung cancer
Of the 175 accompanying malignancies, the most fre-
quent accompanying malignancy was colon cancer
(25/175), followed by rectal cancer (18/175), esopha-
geal cancer (17/175) and thyroid cancer (13/175). The
patients comprised 125 men and 50 women, giving a
sex ratio of 2.5:1. The different types of accompanying
malignancies are presented in Table 2. There were 67
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accompanying malignancies that received curative
treatment, 108received palliative treatment, The cura-
tive treatment rate of accompanying malignancies was
only 38.3 %(67/175). There were 122 accompanying
malignancies that underwent surgery, and the percent-
age of accompanying malignancies addressed with
operation versus non-surgery were 64.6 %(113/175)
and 35.4 %(62/175), respectively. For accompanying
malignancies of the digestive system, there were signifi-
cantly more LCF MPM patients than OCF MPM patients
(32/49,65.3 % vs. 48/126,38.1 %, P = 0.001) and signifi-
cantly more synchronous cases than metachronous cases
(37/64,57.8 % vs. 43/111,38.7 %, P = 0.018). For accom-
panying malignancies in the urogenital system, there were
more metachronous cases than synchronous cases (26/
111,23.4 % vs. 7/64,10.9 %, P = 0.046) and more OCF
MPM patients than LCF MPM patients (30/126,23.8 % vs.
3/49,6.1 %, P = 0.009; Table 2).
Univariate and multivariate analyses of prognosis
The 1- and 5-year OS of patients with 175 MPM involving
lung cancer were 92 % and 59 %, respectively. The 5-year
OS rates for patients with metachronous and synchronous
MPM were 68 % and 38 % respectively (P < 0.001). Meta-
chronous MPM patients demonstrated significantly better
OS than synchronous MPM patients (Fig. 1), with a me-
dian OS of 72.8 (range 12.2–391.0) and 12.9 (range 0.8–
86.3) months, respectively (P < 0.001). The median OS
rates were 39.8 (range 0.8–391.0) months and 43.1 (range
3.9–341.9) months in male and female MPM patients,
respectively; the difference was not significant between
sexes (P = 0.15). The effects of clinical factors on prognosis
were also evaluated. Higher stage, time of occurrence
(synchronous MPM), and order of occurrence (LCF
MPM) were significantly associated with poorer OS.
Moreover, Cox regression modeling revealed that the time
of occurrence and stage were independent factors for OS
(Table 3). We split the MPM patients based on the
order of occurrence to compare OS between the
metachronous and synchronous patients. In LCF
MPM patients, OS between metachronous MPM
patients and synchronous MPM patients did not
reach statistical significance (P = 0.31), with a median
OS of 47.5(range 12.2–243.7) months and 13.0 (range
0.8–48.7) months, respectively. In OCF MPM pa-
tients, metachronous MPM patients showed a statisti-
cally significant improvement in OS than synchronous
MPM patients (P < 0.001), with a median OS of 76.1
(range 12.2–391.0) months and 12.7 (range 0.9–86.3)
months, respectively.
Table 1 Clinical characteristics of the 175 MPM patients with accompanying malignancies










<70Y 111(63.4 %) 47(73.4 %) 64(57.7 %) 30(61.2 %) 81(64.3 %)
> = 70Y 64(36.6 %) 17(26.6 %) 47(42.3 %) 19(38.8 %) 45(35.7 %)
Gender 0.49 0.85
Male 125(71.4 %) 48(75.0 %) 77(69.4 %) 36(73.5 %) 89(70.6 %)
Female 50(28.6 %) 16(25.0 %) 34(30.6 %) 13(26.5 %) 37(29.4 %)
Smoking status 0.043 0.15
Never smoker 119(68.0 %) 37(57.8 %) 82(73.9 %) 29 (59.2 %) 90(71.4 %)
smoker 56(32.0 %) 27(42.2 %) 29(26.1 %) 20(40.8 %) 36(28.6 %)
Histological type 0.88 0.19
adenocarcinoma 106(60.6 %) 40(62.5 %) 66(59.5 %) 27(55.1 %) 79(62.7 %)
Squamous cell carcinoma 45(25.7 %) 16(25.0 %) 29(26.1 %) 18(36.7 %) 27(21.4 %)
SCLC 17(9.7 %) 5(7.8 %) 12(10.8 %) 3(6.1 %) 14(11.1 %)
Other NSCLC 7(4.0 %) 3(4.7 %) 4(3.6 %) 1(2.0 %) 6(4.8 %)
Stage for lung cancer 0.34 0.076
I 42(24.0 %) 20(31.3 %) 22(19.8 %) 10(20.4 %) 32(25.4 %)
II 29(16.6 %) 10(15.6 %) 19(17.1 %) 8(16.3 %) 21(16.7 %)
III 38(21.7 %) 14(21.9 %) 24(21.6 %) 17(34.7 %) 21(16.7 %)
IV 66(37.7 %) 20(31.3 %) 46(41.4 %) 14(28.6 %) 52(41.3 %)
Tumor interval Median(range) 19.3(0.00-391.0) 0.52(0.00-5.1) 49.0(6.03-391.0) <0.001 2.07(0.00-152.2) 36.0(0.00-391.0) <0.001
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EGFR mutation detection
Of 175 MPM patients, there were only 84 patients
who had EGFR mutation status, 25 cases were de-
tected by the methods of direct sequencing while 59
cases were detected by the methods of ARMS, There
are only 84 patients subjected to EGFR mutation ana-
lysis because EGFR mutation analysis was not becom-
ing the routine clinical practice until 2009, what’s
more, the quality and quantity of a portion of lung
cancer specimens was unqualified or not enough for
the EGFR mutation analysis and these patients denied
re-biopsy or the performance status(PS) was not suit-
able for re-biopsy. Of the 84 patients, there were only
24 patients with EGFR mutations for an EGFR muta-
tion rate of only 28.6 %.
Discussion
MPM incidence has increased significantly owing to
advances in diagnostic methods and new therapies, such
as targeted therapies, which allow more patients to sur-
vive long enough to develop subsequent primary tumors
[9, 10], screening procedures are useful for the early de-
tection of possible MPM, especially for the patients who
are diagnosed in advanced stages [11]. Although there
are numerous reports addressing the clinical features of
MPM, only a few studies in Taiwan and Japan have
investigated MPM involving lung cancer [12, 13]. Unfor-
tunately, these reports have only marginally improved our
understanding of the clinical features of patients with this
disease. Therefore, this retrospective study was designed
to evaluate the clinical characteristics and outcomes of












Digestive system 80(45.7 %) 37(57.8 %) 43(38.7 %) 0.018 32(65.3 %) 48(38.1 %) 0.001
Colon 25 9 16 5 20
Rectum 18 5 13 7 11
Esophagus 17 8 9 5 12
Liver 9 6 3 6 3
Stomach 9 9 0 9 0
Duodenal 1 0 1 0 1
Gallbladder 1 0 1 0 1
Urogenital system 33(18.9 %) 7(10.9 %) 26(23.4 %) 0.046 3(6.1 %) 30(23.8 %) 0.009
Urinary bladder 10 2 8 1 9
Prostate 5 0 5 1 4
Uterine cervix 7 1 6 0 7
Kidney 4 1 3 1 3
Ovary 4 2 2 0 4
Endometrium 3 1 2 0 3
Head&Neck 34(19.4 %) 12(18.7 %) 22(19.8 %) 1.00 9(18.4 %) 25(19.8 %) 0.84
Thyroid gland 13 6 7 6 7
Larynx 8 2 6 2 6
Nasopharynx 9 2 7 0 9
Parotid gland 1 1 0 0 1
Tongue 2 0 2 0 2
Soft palate 1 1 0 1 0
Lymphatic&hemat-opoietic system 11(6.3 %) 4(6.3 %) 7(6.3 %) 1.00 2(4.1 %) 9(7.2 %) 0.73
Lymphoma 8 3 5 1 7
Leukemia 3 1 2 1 2
Others 17(9.7 %) 4(6.3 %) 13(11.7 %) 0.30 3(6.1 %) 14(11.1 %) 0.41
Breast 10 3 7 1 9
Skin 5 1 4 1 4
Nasal olfactory cell 1 0 1 0 1
Osteosarcoma 1 0 1 1 0
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MPM patients involving lung cancer in Chinese patients.
The incidence of MPM patients involving lung cancer in
our study was 3.4 % (185/5405), similar to the results of a
previous study from Turkey, which found an incidence of
3.9 % (40/1038) [14]. The most frequent accompanying
malignancies were colon, rectal, and esophageal cancers,
which suggests that lung cancer may be closely associated
with digestive system neoplasms. The next most frequent
accompanying malignancies were thyroid, liver, breast,
urinary bladder, and laryngeal cancers, a distribution simi-
lar to cancers in the general Chinese population. Rare
accompanying malignancies, such as cancers of duodenal,
gallbladder, tongue, soft palate, nasal olfactory cell, and
osteosarcoma, were also identified. In addition, the ob-
served male predominance, with a sex ratio of 2.5:1 for
MPM patients, is consistent with a previous report of
male/female ratios ranging from 0.9:1 to 3.5:1 [15]. More-
over, there were 119 non-smokers (68 %) and 56 smokers
(32 %), which suggests that unknown factors other than
tobacco play an important role in the increased incidence
of MPM. It is well established that a high incidence of
epidermal growth factor receptor (EGFR) mutations is
associated with clinical features, such as adenocarcinoma
histology, Asian ethnicity, female sex, and never-smoker
status [16–18], and MPM patients with nearly 60 %
adenocarcinoma histology and nearly 70 % never-smoker
status indicate the high possibility of EGFR mutations,
which might explain the increased incidence of MPM pa-
tients involving lung cancer. Based on these results, we
reviewed the EGFR mutation status of lung cancer speci-
mens, however, we did not have complete EGFR mutation
data because our sample set included early records from
when EGFR mutation detection was not routine clinical
practice. In fact, there were only 84 patients who had
EGFR mutation status detected by amplification refractory
mutation system-polymerase chain reaction and direct se-
quencing, and there were only 24 patients with EGFR mu-
tations for an EGFR mutation rate of only 28.6 %. This is
similar to the common Asian population, which suggests
that EGFR mutations are not responsible for the increased
incidence of MPM patients involving lung cancer.
In the univariate analysis, we demonstrated no OS
difference between male and female patients, which is
different from one reported study showing better OS in
female patients [10]. The discrepancy may be the result
of the different types of tumors and heterogeneity of the
study populations. Our study suggests that time of
occurrence and stage are independent factors for OS in
MPM patients. Metachronous MPM patients had a bet-
ter prognosis than synchronous MPM patients. This is
consistent with previous studies of MPM involving lung
cancer [12] and MPM involving other cancers, such as
gastric cancer and hepatocellular carcinoma [19–21],
and it is because of detection of the second primary can-
cer at a curable stage with periodic medical check-ups
for patients with a history of cancer. However, there
were 70 patients (63 %) in the metachronous group with
stage III or IV lung cancer and only 34 patients (53.2 %)
in the synchronous group. We believe that the following
reasons can explain this contradiction. First, time of
occurrence other than stage is the most important deter-
mining factor of MPM patient prognosis, which was
shown in the multivariate analysis. Second, there were
18 LCF MPM patients and 93 OCF MPM patients in the
metachronous group. More OCF MPM patients were
observed in the metachronous group, which suggests a
better prognosis.
There are several studies focusing on the difference
between synchronous and metachronous groups, such as
MPM involving lung cancer and MPM involving gastric
cancer and hepatocellular carcinoma, however, to the
best of our knowledge, only one study has focused on
the difference between LCF and OCF groups [12], which
did not show a significant difference either calculated
Fig. 1 Metachronous MPM patients demonstrated significant better
OS than synchronous MPM patients, with median OS rates of 72.8
(range 12.2–391.0) and 12.9 (range 0.8–86.3) months, respectively
(P < 0.001), which suggests that metachronous MPM patients have a
better prognosis than synchronous MPM patients
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time from the diagnosis of the first cancer or from the
second cancer. In this study, the prognosis did not show
a significant difference between LCF and OCF MPM pa-
tients on multivariate analysis, which is consistent with
the previous study. Based on the order of occurrence,
we split MPM patients to compare the OS between the
metachronous and synchronous patients either in LCF
MPM or in OCF MPM patients. Our results showed that
metachronous MPM patients have better OS than syn-
chronous MPM patients in the OCF MPM group, but it
did not show a significant difference in the LCF MPM
group, which suggests that lung cancer is more aggres-
sive than other malignancies. In addition, Zeng et al.
reported no difference in OS between patients with
MPM involving hepatocellular carcinoma (HCC) and pa-
tients with HCC alone [22], indicating that extrahepatic
primary malignancies had no effect on the survival of
HCC patients. For these reasons, MPM patients do not
always have a poor prognosis, especially patients with
metachronous MPM.
Although the underlying mechanisms of MPM have
not been fully elucidated, inherited predisposition is
thought to be an important factor [23]. Such predisposi-
tions include Lynch syndrome, an autosomal dominant-
inherited disorder of colorectal cancer, and susceptibility
to other tumors caused by germline mutations in DNA
mismatch repair genes [24]. The immune system of
patients was suggested to be another important factor
[25], and intensive exposure to carcinogens including
chemotherapy and/or radiotherapy used in the treatment
of tumors [26, 27] and field cancerization in organs
exposed to carcinogens, leading to the proliferation of
Table 3 Univariate and multivariate survival analysis of prognostic factors in MPM patients
Characteristics OS rate (%) Univariate Multivariate
1Y 5Y P value HR(95 % CI) P value
Age(years) 0.95 1.16(0.61-2.21) 0.65
<70Y 94 % 68 %
> = 70Y 91 % 67 %
Gender 0.15 1.05(0.54-2.03) 0.89
Male 90 % 66 %
Female 98 % 70 %
Smoking status 0.28 0.74(0.38-1.45) 0.38
Never smoker 95 % 70 %
Smoker 88 % 63 %
Stage for lung cancer <0.001 1.66(1.38-2.03) <0.001
I 93 % 91 %
II 100 % 79 %
III 95 % 55 %
IV 88 % 55 %
Treatment for other cancers 0.14 1.21(0.75-1.95) 0.44
Curative 94 % 75 %
Palliative 92 % 63 %
Histological type 0.16 1.14(0.92-1.43) 0.24
Adenocarcinoma 93 % 69 %
Squamous cell carcinoma 93 % 67 %
SCLC 88 % 53 %
Other NSCLC 100 % 86 %
Time of occurrence <0.001 0.19(0.10-0.36) <0.001
Synchronous 80 % 61 %
metachronous 100 % 71 %
Order of occurrence 0.047 0.85(0.49-1.47) 0.56
LCF 88 % 63 %
OCF 94 % 69 %
OS Overall Survival; HR Hazard Ratio; CI Confidence Interval
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numerous primary tumors, have also been suggested to
be responsible for MPM [28, 29].
Recently, “ALKoma” was proposed as a cancer sub-
type with a shared target as an essential growth driver
[30]. More and more investigators suggest that cancers
of different organs of origin, but with the same molecu-
lar targets, should be managed together because the
common molecular targets observed in diverse tumors
determine clinical practice better than organ-based
classification [31]. Consequently, further genetic and
molecular studies using next-generation sequencing
explored whether MPM involving lung cancer share
common molecular targets, such as EGFR, Kirsten rat
sarcoma viral oncogene homolog (KRAS) and anaplastic
lymphoma kinase (ALK) to improve therapeutic outcome.
Further genetic and molecular investigations will focus on
understanding the pathogenesis of MPM involving lung
cancer and improving therapeutic outcomes.
There are two new features in the present study that
differ from previous reports. First, this study had the
largest number of MPM cases involving lung cancer in
mainland People’s Republic of China. Second, it is the
first study to explore the impact of both time of tumor
occurrence (synchronous MPM vs. metachronous MPM)
and order of tumor occurrence (LCF MPM vs OCF
MPM) on the survival of MPM patients. Our results
show that metachronous MPM patients have a better
prognosis compared with synchronous MPM patients,
6 months intervals may partially explained why meta-
chronous MPM patients have a better prognosis than
synchronous MPM patients.
Although our study revealed some unique results, there
are some potential shortcomings and limitations. First, the
study was retrospective and was conducted at a single
institution. Second, the study did not explore the impact of
extrapulmonary primary malignancies on lung cancer sur-
vival. Third, some information was deficient because of the
long follow-up duration. Nonetheless, the consistency with
reported studies confirms the validity of our conclusions.
Conclusions
Colorectal cancer, esophageal cancer, and thyroid cancer
were the tumors most frequently accompanying lung
cancer. Time of occurrence and stage were independent
factors for OS, which suggests that MPM patients pre-
senting with metachronous cancers and early stage have
a better prognosis.
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